{"id":"NCT00450437","sponsor":"Novartis Vaccines","briefTitle":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults","officialTitle":"A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2007-08","completion":"2008-01","firstPosted":"2007-03-22","resultsPosted":"2010-09-24","lastUpdate":"2015-01-28"},"enrollment":3539,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Infections","Meningococcal Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"MenACWY CRM","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningococcal ACWY Conjugate vaccine","otherNames":[]}],"arms":[{"label":"Licensed Meningococcal Vaccine","type":"ACTIVE_COMPARATOR"},{"label":"Novartis MenACWY Conjugate Vaccine","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.","primaryOutcome":{"measure":"Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years","timeFrame":"28 days after vaccination","effectByArm":[{"arm":"Novartis MenACWY Lot 1","deltaMin":29,"sd":null},{"arm":"Novartis MenACWY Lot 2","deltaMin":33,"sd":null},{"arm":"Novartis MenACWY Lot 3","deltaMin":31,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":["19476428","19812260"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":2649},"commonTop":["Injection site pain","Headache","Myalgia","Injection site erythema","Injection site induration"]}}